Modern science has identified some of the active components of such sacraments, which has provided for limited research opportunities. Scientific research on these substances is currently very restricted by the U.S. Government's social agendas. Further research on entheogenic compounds coupled to dream state research will offer scientific advance in the study of dreams as well as cultural advances in understanding the value of entheogenic substances for therapeutic and religious use...
The striking similarity of entheogenic experiences to dream experiences tempts us to seek answers as to whether the benefits of dreaming are potentially linked to the benefits of entheogens. The molecular action of visions produced by dreaming is quite possibly very similar to visions produced by entheogenic drugs. Carefully designed research could lend great insight into the mystery of dreaming, the potential therapeutic value of entheogens, and the potential for neurochemical advances.
Serotonin has also been known for some time to play a role in sleep regulation. Numerous recent findings specifically implicate the 5-HT1 and 5-HT2 receptors in regulating sleep (Pastel et al. 1993; Sommerfelt et al. 1993, Tortella et al. 1989; Sharpley et al. 1994, 1990; Dijk et al. 1989; Kirov et al. 1995; Seifritz et al. 1996; Loas 1991). Sleep studies monitoring the effects of selective 5-HT1 and 5-HT2 agonists and antagonists administration in humans and laboratory animals have had impressive findings. It has been shown that the post-synaptic stimulation of 5HT1A receptors suppress REM sleep and increase slow wave (NREM) sleep in humans and laboratory animals (Seifritz et al. 1996; Loas 1991). Additionally, recent evidence establishes that antagonists at the 5HT2 receptors caused identical disruptions in sleeping pattern (Pastel et al. 1993; Sommerfelt et al. 1993, Tortella et al. 1989; Sharpley et al. 1994, 1990; Dijk et al. 1989; Kirov et al. 1995). In other words, when the relative activation of 5-HT2 to 5-HT1 was reduced, REM sleep (where the longest and most vivid dreams take place) was suppressed. Therefore, the relative activation of 5HT2 pathways compared to other 5HT pathways is implicated in REM sleep activation. The subjective experience of dreaming is likely a result of that activation, much like the pathway responsible for the effects of entheogenic drugs.
This data suggests a need for REM sleep but does not suggest what that need is. The most interesting findings are the symptoms of REM sleep deprivation (note that these subjects had full nights of sleep, but no REM sleep): Anxiety, irritability, difficulty concentrating, increased appetite, and even daytime hallucinations.
The data at this point is admittedly modest. It is provocative enough, however, to encourage further research on the subject. The relaxing of legal restrictions on entheogen research would contribute to the collection of quality data on the subject. Dreaming studies that administer entheogens and other powerful 5HT-2 agonists should prove useful in explaining dream/entheogen induced visions. Additionally, methods that allow for complete dream deprivation studies and scanning studies that monitor the activity of 5-HT pathways while the subject is dreaming could prove useful.